BioSpace News Archive

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that the Company will release its third quarter 2023 financial results before the opening of the U.S. financial markets on Monday, November 6, 2023.

ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences as follows.

Voyager Therapeutics, Inc. today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023.

Tonix Pharmaceuticals Holding Corp. announced data from two oral presentations which were delivered recently at the ACS Clinical Congress 2023, and The IPITA, the International Xenotransplantation Association, and the Cell Transplant and Regenerative Medicine Society Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital in October 2023.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announces that it will be showcasing both its CDMO services, marketed under the brand Scinai Bioservices.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will release its third quarter 2023 financial results and a business update on November 9, 2023 at 8:00 am Eastern Time.

Calidi Biotherapeutics, Inc. today announced the appointment of Andrew Jackson as Chief Financial Officer.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced positive top-line results from the MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT not amenable to surgery.

Evecxia Therapeutics, Inc. today announced the appointments of Allan L. Shaw and Elliot Ehrich, MD to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry.

Analysts, investors, and the media are invited to a presentation of RaySearch’s interim report for the third quarter of 2023 on November 17, 2023, at 10.00 am CET.